Background: Thlaspi arvense Linn, belonging to the dicotyledonous cruciferous family, is distributed Europe and Asia. In this study, we evaluated for the first time the anti-inflammatory effects of Thlaspi arvense Linn on LPS-stimulated RAW264.7 macrophages, and explored the related mechanism.Methods: The extract was identified and quantified using the HPLC, NMR. The anti-inflammatory activities of crude extracts C11, C12, C13 were screened by xylene-induced ear swelling and carrageenan-induced foot swelling in mice. The inflammatory mediators, pro-inflammatory cytokines and TLR-4-mediated signals in LPS-stimulated RAW264.7 macrophages were determined using NO activity assay, MTS, ELISA and Western blot.Results:The extract of Thlaspi arvense Linn was found to enrich flavonoid(mainly Orientin,Isoorientin,Vitexin;,Isovitexin,Luteolin-7-O-β-D-glucoside,Apigenin-7-O-β-D-glucoside,Luteolin,Apigeni).5,7-dihydroxy-flavone-4′-(6′′-β-O-glucopyranoside)-β-O-D-glucopyranoside was novel, whereas isosapogenin and 8-methoxyvitexin were isolated for the first time from Thlaspi arvense Linn. The extract (flavonoid-enriched) inhibited xylene-induced ear swelling and carrageenan-induced foot swelling in mice. And suppressed LPS-induced overrelease of iNOS,TNF-α,COX-2 and IL-6 in RAW264.7 macrophages. The extract inhibited the inflammatory response through the signaling pathway mediated by TLR-4/NF- kappa B pathway and its downstream signals, IκB-α, NF-κB-P65 and IL-1β in LPS-stimulated macrophages.Conclusions: The present results demonstrate that the extract of Thlaspi arvense Linn inhibit inflammatory responses via the TLR-4/NF-KB-mediated signaling pathway.
Involved in mediating the folding and maturation of more than 300 client proteins, many of which are oncoproteins, Hsp90 has emerged as a promising drug target for cancer therapy. In particular, inhibiting Hsp90 plays a vital role in the treatment of non‐small cell lung cancer. Owing to undesirable outcomes of Hsp90 inhibitors in clinical trials, a series of matrinic acid compounds bearing 2‐anilinothiazole moiety were designed based on the structural features allocation shared among Hsp90 inhibitors within the ATP‐binding pocket. Most of the compounds showed potent anticancer activities validated by MTT assay. Among them, the most potent compound C4 (IC50 < 10 μM against four cell lines) was chosen for further mechanism study. Notably, C4 showed a better safety profile than 17AAG with a higher SI value. Thermal shift assay data indicated C4 exhibited a strong binding affinity with Hsp90 (−18.85 ± 0.56°C) comparable to radicicol. Mechanism studies verified that C4 significantly inhibited proliferation and migration activities of A549 cells. Besides, C4 can induce a prolonged G1‐phase and cell apoptosis. Western blot analysis results indicated C4 could moderately suppress Hsp90 and upregulate Hsp70 expression. Furthermore, the downregulated trend of the client proteins of Hsp90, such as β‐Catenin and Bcl‐2, were consistent with the cellular effect of C4, suggesting that C4 could exert anticancer activity via targeting Hsp90. In the xenograft model in vivo, C4 effectively inhibited lung cancer growth without obvious side effects. Collectively, C4 could be a promising therapeutic agent for lung cancer and the novel scaffold provided new insights into the design of Hsp90 inhibitors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.